Technology-Enabled Genomics

The study of genomics lies at the crux of science and medicine, offering us an opportunity to fundamentally change the way we address patient stratification and drug development, and how we implement target identification and validation practices.

Whole genome sequencing provides a valuable tool for the future of personalized medicine to help pinpoint functional variants from association studies with phenotypic data and better understand how genomics influence phenotypes to inform drug development decision-making. Through strategic collaborations and rigorous analysis, we are developing comprehensive data sets to ensure we understand and can help patients of all backgrounds.

• Janssen R&D is among the founding life sciences partners for Our Future Health, which aims to recruit up to five million adults from across the United Kingdom (UK) to create one of the world’s largest, most comprehensive and most diverse longitudinal health data sets. This effort will support important research to help develop new ways to prevent, detect and treat a variety of diseases and health conditions. A major focus will be developing approaches for identifying diseases such as cancer and heart disease before they become symptomatic.
   
• Janssen R&D partnered with a consortium of pharmaceutical partners in collaboration with the UK Biobank. This project, based on a vast constellation of phenotype data collected on 500,000 individuals in the UK for the past 15 years, will read and assemble the genomic sequences of these volunteers in order to facilitate population-based association studies.

We understand the power of being better together, building collaborations uniquely designed to help address the problems we seek to solve. And as our world continues evolving, we are always learning, inspired by people and teams across industries who are harnessing innovation so more people can have the medicines they need.